title: Words of wisdom: Re: High-risk prostate cancer treated with pelvic radiotherapy and 36 versus 18 months of androgen blockade: results of a phase III randomized study [abstract 3].
authors.affiliation: Department of Radiation Oncology, University Hospital, Joseph Fourier University, Grenoble, France. MBolla@chu-grenoble.fr
authors.forename: Michel
authors.initials: M
authors.lastname: Bolla
mesh_terms: D000726:Androgen Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use*; D059248:Chemoradiotherapy / Q000009:adverse effects / Q000401:mortality; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D008297:Male; D009376:Neoplasms, Hormone-Dependent / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D011471:Prostatic Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D011879:Radiotherapy Dosage; D020266:Radiotherapy, Conformal / Q000009:adverse effects / Q000401:mortality; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal